Comparative Pharmacology
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus QUILLIVANT XR.
LISDEXAMFETAMINE DIMESYLATE vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisdexamfetamine is a prodrug of dextroamphetamine, which blocks the reuptake of norepinephrine and dopamine from the synaptic cleft and increases their release into the extraneuronal space.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
30–70 mg orally once daily in the morning.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Terminal elimination half-life of lisdexamfetamine is approximately 1 hour (prodrug conversion), while dextroamphetamine (active moiety) has a half-life of 10-12 hours in adults. In children, half-life is slightly shorter (9-11 hours). Clinically, once-daily dosing provides symptom control for ADHD.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Primarily renal: approximately 95% of the dose is excreted in urine, with about 70% as intact lisdexamfetamine, 20% as dextroamphetamine and its metabolites (hippuric acid, benzoic acid), and minimal biliary/fecal elimination (<5%).
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant